Fluzone High Dose vaccine results for Influenza is published in NEJM- Sanofi Pasteur
Sanofi Pasteur, the vaccines division of Sanofi announced that The New England Journal of Medicine published positive results from a large-scale, multi-center efficacy trial, which found that Fluzone High-Dose (Influenza Vaccine) was more efficacious in preventing influenza (�the flu�) in adults 65 years of age and older compared to standard-dose Fluzone vaccine.
Fluzone High-Dose vaccine was found to be 24.2 percent (95% CI, 9.7 to 36.5) more effective in preventing influenza relative to standard-dose Fluzone vaccine for the primary endpoint, indicating that about one in four breakthrough cases of influenza could be prevented if Fluzone High-Dose vaccine were used instead of the standard-dose Fluzone vaccine in this population. Additionally, relative efficacy was 35.4 percent (95% CI, 12.5 to 52.5) in an analysis restricted to influenza cases caused by vaccine-similar strains. Fluzone High-Dose vaccine is an inactivated influenza vaccine that contains four times the amount of antigen than is contained in standard-dose Fluzone vaccine and induces a higher antibody response.
"Efficacy of High-Dose versus Standard-Dose Influenza Vaccine in Older Adults -August 14, 2014-Diaz Granados C.A., Dunning A.J., Kimmel M., et al.N Engl J Med 2014; 371:635-645.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins